Replicate Bioscience
San Diego
About Replicate Bioscience
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) technology to enhance the effectiveness of RNA-based therapeutics beyond traditional mRNA approaches. Its platform is designed to deliver stronger biological activity, more durable immune responses, and an improved therapeutic index. The company’s lead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $53.0M
- Funding stage: Early Stage Venture
- Last round: Grant (Jan 2026)
- Website: replicatebioscience.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/replicate-bioscience-43108 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.